Femasys (FEMY) Convertible Debt (2023 - 2025)

Femasys' (FEMY) quarterly Convertible Debt came in at $3.2 million in Q4 2025, down 37.28% on a QoQ basis from $5.1 million in Q3 2024.

Femasys (FEMY) Convertible Debt (2023 - 2025) Analysis & Trends

Femasys (FEMY) has 3 years of Convertible Debt data on file, last reported at $3.2 million in Q4 2025.

Quarterly Convertible Debt changed N/A year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.2 million, changed N/A from the prior year.
Convertible Debt fell to $3.2 million in Q4 2025, from $5.1 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $5.1 million in Q3 2024 to a low of $3.2 million in Q4 2025.
A 3-year average of $4.3 million and a median of $4.5 million in 2024 frame the typical range for Convertible Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn
10	Femasys	8.98 Mn	7.54 Mn	189,391.00

Download Data